Advice from the independent data monitoring committee (IDMC) that Axsome Therapeutics Inc. quit the phase III trial called CREATE-1 with AXS-02 (disodium zoledronate tetrahydrate) put a dent in the company's shares and reshuffled the landscape for complex regional pain syndrome (CRPS) candidates.